Abstract #2165
Gadoxetate contrast kinetics are altered in rat liver by a peptide deformylase inhibitor known to induce phospholipidosis
Stephen Clark Lenhard 1 , Mary Rambo 2 , Ciara Rodgers 2 , Mark Burgert 2 , Lindsey Webster 3 , Richard Peterson 3 , Richard Miller 3 , and Beat Jucker 2
1
GlaxoSmithKline, King of Prussia, PA, United
States,
2
GlaxoSmithKline,
PA, United States,
3
GlaxoSmithKline,
NC, United States
Phospholipidosis (PLD) is a generalized condition in
humans and animals characterized by an intracellular
accumulation of phospholipids. Using a clinically
available liver specific MRI contrast agent (Eovist;Gadoxetate),
hepatobiliary Dynamic Contrast Enhanced MRI (DCE-MRI)
was performed to determine if Gadoxetate kinetic changes
could be detected with a compound known to induce PLD.
Gadoxetate DCE MRI of liver function may be a useful
pre-clinical technique to assess hepatic functional
consequences of PLD in vivo to support drug development
decisions for compounds found to induce PLD.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Click here for more information on becoming a member.
